Publikationen in Zusammenarbeit mit Forschern von Tel Aviv University (37)

2024

  1. Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study

    United European Gastroenterology Journal

  2. Effectiveness of Helicobacter pylori Treatments According to Antibiotic Resistance

    American Journal of Gastroenterology, Vol. 119, Núm. 4, pp. 646-654

  3. Upper and/or Lower Respiratory Tract Infection Caused by Human Metapneumovirus After Allogeneic Hematopoietic Stem Cell Transplantation

    Journal of Infectious Diseases, Vol. 229, Núm. 1, pp. 83-94

2023

  1. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

    New England Journal of Medicine, Vol. 389, Núm. 4, pp. 335-347

  2. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

    Blood, Vol. 141, Núm. 3, pp. 219-230

  3. Empirical rescue treatment of Helicobacter pylori infection in third and subsequent lines: 8-year experience in 2144 patients from the European Registry on H. pylori management (Hp-EuReg)

    Gut, Vol. 72, Núm. 6, pp. 1054-1072

  4. Ichthyosis

    Nature Reviews Disease Primers, Vol. 9, Núm. 1

  5. Idiopathic Thrombocytopaenic Purpura associated with Inflammatory Bowel Disease: a multicentre ECCO CONFER case series

    Journal of Crohn's and Colitis, Vol. 17, Núm. 5, pp. 722-727

  6. Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

    Blood

  7. Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

    eClinicalMedicine, Vol. 65

  8. Transcatheter aortic valve implantation in patients with extra-small aortic annuli

    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, Vol. 19, Núm. 4, pp. e340-e351

2022

  1. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

    The Lancet. Haematology, Vol. 9, Núm. 6, pp. e403-e414

  2. Comparison of Outcomes after Unrelated Double-Unit Cord Blood and Haploidentical Peripheral Blood Stem Cell Transplantation in Adults with Acute Myelogenous Leukemia: A Study on Behalf of Eurocord and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

    Transplantation and Cellular Therapy, Vol. 28, Núm. 10, pp. 710.e1-710.e10

  3. Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg)

    Clinical Gastroenterology and Hepatology, Vol. 20, Núm. 10, pp. 2243-2257

  4. Gastroenteropancreatic Neuroendocrine Neoplasms in Patients with Inflammatory Bowel Disease: An ECCO CONFER Multicentre Case Series

    Journal of Crohn's and Colitis, Vol. 16, Núm. 6, pp. 940-945

  5. Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors

    American Journal of Hematology, Vol. 97, Núm. 7, pp. 877-884

  6. Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

    Blood, Vol. 140, Núm. 21, pp. 2248-2260

2021

  1. Cancer drug resistance induced by EMT: novel therapeutic strategies

    Archives of Toxicology, Vol. 95, Núm. 7, pp. 2279-2297

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  3. Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group

    Leukemia, Vol. 35, Núm. 12, pp. 3585-3588